Protocol - On-site Urine Drug Screen

Add to My Toolkit

A CLIAwaived Multidrug Cup is an immunochromatographic assay for rapid, on-site qualitative detection of drug combinations and their principal metabolites in urine at specified cut-off concentrations, based on the Substance Abuse and Mental Health Services Administration (SAMHSA) drug cut-off concentrations. The multidrug cup may be used to test any number of drugs (amphetamine, barbiturates, benzodiazepines, cocaine, marijuana, methadone, methamphetamine, opiates, oxycodone, phencyclidine, and tricyclic antidepressant).

Specific Instructions:

This protocol can be combined with the "Duration of Abstinence – Substance Use" protocol to support or refute a subjects response, and thus improve the validity of self-report.

Further, this protocol provides only preliminary data which may be confirmed by other methods such as gas chromatography/mass spectrometry (GC/MS) used in the "Lab-Based Urine Drug Analysis" measure. Clinical considerations and professional judgment should be applied to any drug test result, particularly when preliminary positive results are indicated.

The Substance Abuse and Addiction Working Group acknowledges that the following questions may gather sensitive information relating to the use of substances and/or illegal conduct. If the information is released, it might be damaging to an individuals employability, lead to social stigmatization, or lead to other consequences.

Most researchers assure confidentiality as part of their informed consent process, as required by their institutional review boards. When assessing minors with these questions, it may be necessary to obtain informed consent from a parent of the adolescent. Further assurance of confidentiality may be obtained by applying to the National Institutes of Health (NIH) for a Certificate of Confidentiality, which helps researchers protect the privacy of human research participants. The procedures for the Certificate of Confidentiality can be found at the Grants Policy website of the NIH: http://grants1.nih.gov/grants/policy/coc/index.htm.


Intended Use

A CLIAwaived Multidrug Cup is an immunochromatographic assay for rapid, qualitative detection of drug combinations and their principal metabolites in urine at specified cut-off concentrations. The multidrug cup may be used to test any number of drugs, from a single drug up to 11 different drugs. The drug combinations may be composed of any of the following drugs, at the noted cut-off concentrations:

Drug Class





1000 ng/ml



300 ng/ml



300 ng/ml



300 ng/ml



50 ng/ml



300 ng/ml



1000 ng/ml



2000 ng/ml



25 ng/ml

Tricyclic Antidepressant


1000 ng/ml

Reagents and Material Provided

1. Test Devices

Contains dye-conjugated antibody and immobilized antigen in protein matrix with sodium azide.

2. Test Instructions

Complete instructions guide can be viewed here: http://www.cliawaived.net/items/addonfiles/1347_CLIA_waived_drug_testing_cup_urine.pdf.


3. Negative Control I

Contains buffered protein solution with sodium azide.

4. Amphetamine Positive Control

Contains AMP at 3000 ng/ml in a buffered protein solution with sodium azide.

5. Barbiturates Positive Control

Contains BAR at 1000 ng/ml in a in a buffered protein solution with sodium azide.

6. Benzodiazepines Positive Control

Contains BZD at 1000 ng/ml in a buffered protein solution with sodium azide.

7. Cocaine Positive Control

Contains COC/BEG at 1000 ng/ml in a buffered protein solution with sodium azide.

8. Marijuana Positive Control

Contains THC at 150 ng/ml in a buffered protein solution with sodium azide.

9. Methadone Positive Control

Contains MAD at 1000 ng/ml in a buffered protein solution with sodium azide.

10. Methamphetamine Positive Control

Contains MET at 3000 ng/ml in a buffered protein solution with sodium azide.

11. Opiates Positive Control

Contains OPI/MORE at 5000 ng/ml in a buffered protein solution with sodium azide.

12. Oxycodone Positive Control

Contains OXY at 300 ng/ml in a buffered protein solution with sodium azide.

13. Phencyclidine Positive Control

Contains PCP at 100 ng/ml in a buffered protein solution with sodium azide.

14. Tricyclic Antidepressant Positive Control

Contains TCA at 3000 ng/ml in a buffered protein solution with sodium azide.

Warnings and Precautions

1. Do not use the test device beyond the expiration date.

2. Urine specimens may be infectious; properly handle and dispose of urine in the toilet by draining it out of the test device. Fasten cap on the device and throw the empty urine cup in the garbage.

3. Visually inspect the foil package to insure it is intact. If the package is not intact, the integrity of the device might be compromised.

Storage and Stability

Store test kit below 28°C, do not freeze. If stored at 2°-8°C, allow the test kit to reach room temperature (15°-28°C) before performing the test. Refer to the expiration date for stability.

Specimen Collection and Preparation

The CLIAwaived Multidrug device employs a thermal strip that should be checked immediately after collection to validate urine specimen. Substance Abuse and Mental Health Services Administration (SAMHSA) regulations specify that any temperature below 90.5°F must be considered adulterated. No additive or preservatives are required.

The Substance Abuse and Addiction Working Group identified the CLIAwaived Multidrug device as being the one used by SAMHSA. To aid comparability, the Working Group recommended that the investigator record the make and manufacturer of the device being used for testing.

Test Procedure

  1. Do not break the seal of the pouch until ready to begin testing.
  2. Remove the test cup from the foil pouch.
  3. Collect urine specimen directly into the test cup. Ensure that the sample amount meets the minimum level as indicated on the side of the test cup.
  4. Read the results at 5 minutes. Do not interpret results after 30 minutes.

Note: The result must be interpreted at five minutes. Waiting more than five minutes may cause the reading to be inaccurate. To avoid confusion, discard the test device after interpreting the result.

Interpretation of Results

Positive: A rose-pink band is visible in each control zone (top band). No color band appearing in the appropriate test zone (bottom band) indicates a preliminary positive result for the corresponding drug of that specific test zone. Send urine specimen to a certified laboratory for confirmation.

Negative: A rose-pink band is visible in each control zone and the appropriate test zone, indicating that the concentration of the corresponding drug of that specific test zone is below the detection limit of the test.

Invalid: If a color band is not visible in each of the control zones, the test is invalid. Another test should be run to re-evaluate the specimen.

Note: There is no meaning attributed to line color intensity or width.

Limitations of the Test

  1. This product is designed to be used for the detection of drugs of abuse and their metabolites in human urine only.
  2. Although the test is very accurate, there is the possibility false results will occur due to the presence of interfering substances in the specimen sample.
  3. The test is a qualitative screening assay and is not suggested for quantitative determination of drug levels in urine, or the level of intoxication.
  4. Adulterants such as bleach or other strong oxidizing agents, when added to urine specimens, can cause erroneous test results regardless of the analysis method used.

If adulteration is suspected, obtain another urine specimen.

Protocol Name from Source:


Publicly available

Personnel and Training Required
Supervised urine collection is required by a same-sex observer
Equipment Needs
Drug test cups, timer or clock.
Requirement CategoryRequired
Major equipment No
Specialized training No
Specialized requirements for biospecimen collection No
Average time of greater than 15 minutes in an unaffected individual No
Mode of Administration


Life Stage:

Adolescent, Adult, Senior


Adolescents and adults aged 13 years and older

Selection Rationale

Urine testing is considered less "biased" than self-report but is less sensitive as a measure of change or predictor of other outcomes. Conversely, self-reported measures of the recency or frequency of use are more sensitive measures of change but also subject to more bias and under-reporting. Combining on-site urine testing with self-report and prompting when they disagree can minimize bias while maximizing sensitivity to change.

The CLIAwaived Multidrug Cup is an easy, fast, on-site, qualitative, visually read competitive binding immunoassay method for screening without the need for instrumentation. The method employs a unique mixture of antibodies to selectively identify the drugs of abuse and their metabolism in test samples with a high degree of sensitivity. The sensitivity of the CLIAwaived Multidrug is set as required for the screening immunoassays of these drugs in the reference guidelines set by the U.S. Substance Abuse and Mental Health Services Administration (SAMHSA) and the U.S. Department of Health and Human Services (DHHS).



Common Data Elements (CDE) Drug Abuse Urine Screening Positive Negative Code 3332426 CDE Browser
Derived Variables


Process and Review

This section will be completed when reviewed by an Expert Review Panel.


For test kits, please contact:

11578 Sorrento Valley Road
Suite 25/26
San Diego, CA 92121

General References

Scott, C. K., & Dennis, M. L. (2009). Results from two randomized clinical trials evaluating the impact of quarterly recovery management checkups with adult chronic substance users. Addiction, 104(6), 989-971.

U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. (2008, November 25). Mandatory guidelines for federal workplace drug testing programs (Section 3.4: Analytes and their cutoffs effective date: October 1, 2010, pp. 71880–71881). Federal Register, 73, 71858–71907.

Protocol ID:


Export Variables
Variable NameVariable IDVariable DescriptionVersiondbGaP Mapping
PX510601_Adequate_Volume_Obtained PX510601060000 Adequate volume of urine was obtained: N/A
PX510601_Amphetamine PX510601070000 Amphetamine N/A
PX510601_Barbiturates PX510601080000 Barbiturates N/A
PX510601_Benzodiazepines PX510601090000 Benzodiazepines N/A
PX510601_Cocaine PX510601100000 Cocaine/Benzoylecgonine N/A
PX510601_Expiration_Date_Day PX510601030100 Expiration date of kit: Day N/A
PX510601_Expiration_Date_Month PX510601030200 Expiration date of kit: Month N/A
PX510601_Expiration_Date_Year PX510601030300 Expiration date of kit: Year N/A
PX510601_Make_And_Manufacturer PX510601020000 Make and manufacturer of the equipment used: N/A
PX510601_Marijuana PX510601110000 Marijuana N/A
PX510601_Methadone PX510601120000 Methadone N/A
PX510601_Methamphetamine PX510601130000 Methamphetamine N/A
PX510601_Opiates PX510601140000 Opiates/Morphine N/A
PX510601_Oxycodone PX510601150000 Oxycodone N/A
PX510601_Phencyclidine PX510601160000 Phencyclidine N/A
PX510601_Temperature_Of_Specimen PX510601010000 Temperature of specimen from the CLIA waived more
Multidrug device thermal strip: ______ F show less
PX510601_Time_Began PX510601040100 Time test began N/A
PX510601_Time_Began_AmPm PX510601040200 Time test began: Am or Pm N/A
PX510601_Time_Ended PX510601050100 Time test ended N/A
PX510601_Time_Ended_AmPm PX510601050200 Time test ended: Am or Pm N/A
PX510601_Tricyclic_Antidepressant PX510601170000 Tricyclic antidepressant N/A
Substance Abuse and Addiction
Measure Name:

On-site Urine Drug Screen

Release Date:

February 24, 2012


Bioassay used to detect recent illegal drug use.


This assay is used to detect whether or not the participant has recently used illegal drugs. Urine drug testing can confirm the presence of a drug or the use of multiple drugs.


Amphetamine, Barbiturates, Benzodiazepines, Bioassay, Buprenorphine, Cannabis, Cocaine, Codeine, Drug, Ecstasy, Heroin, Marijuana, MDA, MDEA, MDMA, Methadone, Methamphetamine, Methylenedioxymethamphetamine, Methylenedioxyamphetamine, Methylenedioxyethylamphetamine, Morphine, Opiates, Phencyclidine, SAA, Substance Use, Tricyclic Antidepressant, Urine, Assessment of Substance Use and Substance Use Disorders